Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation. 2008;118:33-41
Published online before print June 16, 2008, doi: 10.1161/CIRCULATIONAHA.107.721878
CLINICAL PERSPECTIVE
Free Article
This Article
Free upon publication Free Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
118/1/33    most recent
CIRCULATIONAHA.107.721878v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pande, R. L.
Right arrow Articles by Creager, M. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pande, R. L.
Right arrow Articles by Creager, M. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Peripheral Arterial Disease
Related Collections
Right arrow Risk Factors
Right arrow Peripheral vascular disease
Right arrow Epidemiology
Right arrowRelated Article

(Circulation. 2008;118:33-41.)
© 2008 American Heart Association, Inc.

Epidemiology

Association of Insulin Resistance and Inflammation With Peripheral Arterial Disease

The National Health and Nutrition Examination Survey, 1999 to 2004

Reena L. Pande, MD; Todd S. Perlstein, MD, MMSc; Joshua A. Beckman, MD, MSc; Mark A. Creager, MD

From the Department of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Reena L. Pande, MD, Brigham and Women’s Hospital, Cardiovascular Division, 75 Francis St, A Bldg, 3rd Floor, Boston, MA 02115. E-mail rpande{at}partners.org

Received June 15, 2007; accepted August 24, 2008.


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowConclusions
 down arrowReferences
 
Background— Although the role of inflammation in the pathophysiology of peripheral arterial disease (PAD) is well established, the contribution of insulin resistance (IR) to PAD is less clear. We hypothesized that IR is associated with PAD and that the presence of IR would influence the association between C-reactive protein (CRP) and PAD, an association established predominantly in healthy individuals.

Methods and Results— We analyzed data from 3242 adults in the National Health and Nutrition Examination Survey (NHANES) 1999 to 2004 who underwent measurement of ankle brachial index, CRP, and fasting glucose and insulin, enabling calculation of homeostasis model of IR (HOMA-IR). Odds ratios (ORs) and 95% CIs were estimated by logistic regression. The mean prevalence of PAD (defined as an ankle brachial index ≤0.9) was 5.5% (SE, 0.47%). HOMA-IR was independently associated with PAD (OR, 2.06; 95% CI, 1.1 to 4.0; P=0.03 for quartile 4, P for trend across quartiles=0.047) after adjustment for age, gender, race/ethnicity, hypertension, hyperlipidemia, smoking, body mass index, chronic kidney disease, and CRP. Elevated CRP (>3 mg/L) also was strongly associated with PAD (OR, 2.2; 95% CI, 1.3 to 3.6; P=0.003 versus CRP <1 mg/L). Stratifying subjects on the basis of median HOMA-IR, we found that CRP >3 mg/L was no longer significantly associated with PAD in subjects with IR (OR, 1.3; 95% CI, 0.8 to 2.1; P=0.3, P for interaction=0.08).

Conclusions— These findings demonstrate that IR is strongly and independently associated with PAD. Furthermore, IR modifies the association of inflammation with PAD. These data establish a role of IR in PAD and highlight the relative importance of inflammation in patients with and without IR.


Key Words: inflammation • insulin resistance • peripheral vascular disease


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowConclusions
 down arrowReferences
 
Both insulin resistance and inflammation have been implicated in the development of atherosclerosis. The contribution of inflammation to atherogenesis has been demonstrated in both cellular and molecular investigations and confirmed in epidemiological studies demonstrating an association of C-reactive protein (CRP; an inflammatory marker) with increased cardiovascular risk.1–3 Similarly, insulin resistance, increasingly appreciated as an important component of atherogenesis, is associated with clinical atherosclerosis in epidemiological studies and predicts future cardiovascular events.4–8

Clinical Perspective p 41

Peripheral arterial disease (PAD) is an important manifestation of systemic atherosclerosis affecting an estimated 10 million Americans9 and is associated with significant limb morbidity and cardiovascular mortality.10 The role of insulin resistance in PAD is not well established, although several lines of evidence support a linkage. Insulin resistance contributes significantly to the development of diabetes mellitus, a known risk factor for PAD,10 and studies have shown that incident PAD may be associated with the metabolic syndrome11,12 and glucose intolerance,13 both manifestations of insulin resistance. No prior study has evaluated the relationship between PAD and a direct measurement of insulin resistance. The homeostasis model of insulin resistance (HOMA-IR) is a simple measure of insulin resistance derived from fasting glucose and insulin values that correlates well with insulin sensitivity derived from the glucose clamp technique, the gold standard measure of insulin sensitivity.14 HOMA-IR has been shown to correlate with cardiovascular disease6–8 and cerebrovascular disease,15–18 but the relationship between HOMA-IR and PAD has not previously been established.

In contrast to the limited data on insulin resistance and PAD, several studies have shown that inflammatory markers, including CRP, are directly associated with PAD,19,20 predict the initial development of PAD,21,22 and portend adverse outcomes in patients with established PAD.23,24 However, the importance of CRP as a predictor of PAD and cardiovascular disease has been established predominantly in healthy individuals.1,21 In subjects with diabetes or other established cardiovascular risk factors, the association between CRP and vascular disease is less clear. Indeed, conflicting data exist, with several studies demonstrating a significant attenuation of the association between CRP and myocardial infarction or stroke in subjects with diabetes,25,26 although the data are not uniform.27 With these inconsistent findings and the accumulating evidence supporting the close interrelationship of inflammation and insulin resistance,28–30 we hypothesized that the presence of insulin resistance might modify the association between CRP and PAD. Accordingly, we used the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2004 to evaluate the association between HOMA-IR, a direct measure of insulin resistance, and PAD and to determine the influence of insulin resistance on the association of inflammation and PAD.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowConclusions
 down arrowReferences
 
The NHANES is a series of surveys of the noninstitutionalized civilian population in the United States. Sampling is performed in a complex, stratified, multistage manner to provide nationally representative data in an effort to assess the health and nutritional status of adults and children in the United States. The 1999 to 2004 NHANES was reviewed and approved by the National Center for Health Statistics Institutional Review Board. Informed consent was obtained from all subjects.

Ankle Brachial Index Measurements
Beginning in 1999, adults ≥40 years of age were asked to participate in a lower-extremity examination, including the ankle brachial index (ABI), a diagnostic test for PAD with excellent performance characteristics (79% to 95% sensitivity and 95% to 100% specificity).10 Systolic pressure was measured in the supine position in the right arm (brachial artery) and in the posterior tibial artery of both ankles with an 8-MHz Doppler probe. Blood pressures were measured twice at each site in participants 40 to 59 years of age and only once for participants ≥60 years of age. The ABI was calculated by dividing the systolic blood pressure in the ankle by the systolic blood pressure in the arm. We assigned a diagnosis of PAD if either leg had an ABI ≤0.90. Patients with ABI values >1.40 were excluded because these values may be falsely elevated as a result of severe vascular calcification.

Laboratory Methods
Standard automated biochemical analysis was used to determine nonfasting serum glucose (Beckman Synchron LX20, Beckman Coulter, Fullerton, Calif), and fasting glucose was measured with the enzyme hexokinase method. Fasting insulin was determined with the 2-site immunoenzymometric assay (Tosoh AIA-PACK IRI, Tosoh Bioscience Inc, Grove City, Ohio) in 2003 to 2004. For earlier years (1999 to 2002), the Pharmacia insulin radioimmunoassay kit was used for insulin measurement (Pharmacia Diagnostics AB, Uppsala, Sweden). Because these methods yield slightly different measurements, insulin values were converted as recommended in the analytic guidelines.31 High-sensitivity CRP was measured by latex-enhanced nephelometry. Serum creatinine and nonfasting cholesterol values were determined by automated biochemical profiling (Beckman Synchron LX20). Because of a change in assay, serum creatinine values from the 1999 and 2000 examinations were corrected as suggested in the laboratory documentation files. Fasting lipids were analyzed with the Hitachi 704 Analyzer (Roche Diagnostics, Basel, Switzerland). HOMA-IR was calculated as follows: {[fasting glucose (mmol/L)]x[fasting insulin (µU/mL)]}/22.5.32

Covariates
Race/ethnicity, gender, and age were assessed by self-report. Race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, Mexican American, or other. Subjects were considered to have hypertension if they reported a physician diagnosis of hypertension, if they reported taking prescription medications for hypertension, or if systolic blood pressure was ≥140 mm Hg and/or diastolic blood pressure was ≥90 mm Hg. These blood pressures were taken separately from the ABI examination and measured with a mercury sphygmomanometer. A diagnosis of hypercholesterolemia was assigned if the subject reported a physician diagnosis of hypercholesterolemia or reported taking prescription medications for hypercholesterolemia or if the total cholesterol level was ≥6.21 mmol/L (240 mg/dL). Subjects were considered to have diabetes mellitus if the subject reported a physician diagnosis of diabetes, if the subject reported taking prescription medications for diabetes (either insulin or oral agents), if nonfasting plasma glucose was ≥11.1 mmol/L (200 mg/dL), or if fasting plasma glucose was ≥7 mmol/L (126 mg/dL). Active smokers were determined from self-report (a positive answer to the question, "Do you now smoke cigarettes?"). Those who did not meet these criteria were considered former smokers if they answered yes to the question, "Have you smoked at least 100 cigarettes in your life?" and never smokers if they had never smoked in their lifetime. Body mass index (BMI) was calculated as weight (kg) divided by height (m2) (n=3198). We used the Modification of Diet in Renal Disease Study equation to estimate glomerular filtration rate (GFR) from serum creatinine (SCr): GFR (mL · min–1 · 1.73 m–2)=175x (SCr)–1.154x(age)–0.203x(0.742 if female)x(1.210 if black).33 Subjects with an estimated GFR <60 mL · min–1 · 1.73 m–2 were classified as having chronic kidney disease. Diagnosis of congestive heart failure, angina, heart attack, and stroke was made by self-report. Any cardiovascular disease was defined as prevalent myocardial infarction, heart failure, or stroke on the basis of a subject’s affirmative response to the question, "Has a doctor or other health professional ever told you that you have had a [heart attack/congestive heart failure/stroke]?" Subjects were categorized as having the metabolic syndrome on the basis of the National Cholesterol Education Program criteria if they had 3 of the 5 following criteria: high-density lipoprotein <1.04 mmol/L (40 mg/dL) (men) and <1.3 mmol/L (50 mg/dL) (women), waist circumference >102 cm (men) or >88 cm (women), triglycerides >1.7 mmol/L (150 mg/dL), fasting glucose >5.6 mmol/L (100 mg/dL), and elevated blood pressure (systolic >130 mm Hg or diastolic >8 mm Hg).

Derivation of Sample Population
Our analysis combined data from the NHANES 1999 to 2004 examinations. ABI measurements were available for 7571 subjects in NHANES 1999 to 2004, of which 113 were excluded on the basis of ABI >1.40. One half of these participants, a representative subsample of the US population, were asked to attend a morning session during which fasting blood work was collected. Only individuals who had fasted at least 8 to 24 hours were assigned a nonzero fasting weight and thus were included in our sample population.31 This left 3499 with glucose and insulin values enabling calculation of HOMA-IR. We excluded subjects who were taking insulin (n=80) given the limitations of HOMA-IR measurements in this subpopulation.34 After the exclusion of subjects who did not have complete information available on other covariates of interest, the remaining 3242 subjects constituted the sample population for this analysis.

Statistical Methods
NHANES uses a complex, multistage, probability sampling design to select participants representative of the civilian, noninstitutionalized US population. Given that our analysis was limited to the representative subsample of individuals with fasting blood work, we used the fasting sample weights to account for the sampling design. Subjects were included in our analysis only if they had fasted a minimum of 8 hours and had been assigned a nonzero fasting weight. We generated a combined 6-year fasting weight variable by assigning two thirds of the 4-year weight for 1999 to 2002 if the subject participated during 1999 to 2002 or assigning one third of the 2-year weight for 2003 to 2004 if the subject participated during 2003 to 2004.

Analyses were performed with SAS version 9.1 (SAS Institute, Inc, Cary, NC) callable SUDAAN version 9.01 (Research Triangle Institute, Research Triangle Park, NC) to account for the complex sample design. Age- and gender-adjusted baseline subject characteristics are reported as the weighted mean and SE or the weighted percentile and SE. Categorical variables were compared by use of the {chi}2 test or logistic regression. Comparisons of mean values across groups and correlations between continuous variables were achieved by linear regression. Odds ratios (ORs) and 95% CIs were estimated by logistic regression. We divided HOMA-IR values into quartiles and examined the presence of a linear trend across quartiles. We further evaluated the odds of PAD in each quartile compared with the reference group, HOMA-IR quartile 1. In a multivariable model, we then adjusted for age, gender, race/ethnicity, hypertension, hyperlipidemia, smoking, BMI, chronic kidney disease, and CRP. A value of P<0.05 was considered statistically significant except for interaction terms, for which a value of P<0.10 was considered statistically significance.

To assess whether the presence of insulin resistance influenced the relationship between CRP and PAD, we stratified the population by median HOMA-IR level to indicate the presence or absence of insulin resistance and reevaluated the relationship between CRP and PAD in these 2 categories. Given the lack of established threshold values of HOMA-IR to indicate insulin resistance, we used the median HOMA-IR level as a threshold value in our analysis. A formal test for interaction also was performed to evaluate the impact of insulin resistance on the association between CRP and PAD.

The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowConclusions
 down arrowReferences
 
Of the 3242 subjects in our sample population, 256 participants had an ABI ≤0.90, for an overall unadjusted weighted prevalence (mean) of PAD of 5.5% (SE, 0.47%). Age- and gender-adjusted baseline characteristics of participants with and without PAD are summarized in Table 1. Subjects with PAD had a significantly higher mean age (66.4 years [SE, 1.1 years] versus 55.5 years [SE, 0.3 years]; P<0.0001) and a higher prevalence of hypertension, coronary heart disease, and chronic kidney disease. An elevated CRP (>3 mg/L) was noted in a significantly higher proportion of PAD subjects (54.6% [SE, 5.0%] versus 40.3% [SE, 1.0%]), and mean CRP levels were significantly higher in PAD subjects (7.5 mg/dL [SE, 1.3 mg/dL] versus 4.4 mg/dL [0.2 mg/dL]; P=0.02). There were no significant differences in gender distribution or BMI.


View this table:
[in this window]
[in a new window]

  		Table 1. Age- and Gender-Adjusted Subject Characteristics

Association of HOMA-IR and PAD
Age- and gender-adjusted baseline characteristics of subjects in each HOMA-IR quartile are shown in Table 2. Subjects in the higher HOMA-IR quartiles were less likely to be female or of non-Hispanic white race. Cardiovascular risk factors, including hypertension, hyperlipidemia, and diabetes, were significantly more prevalent in increasing HOMA-IR quartiles. A history of smoking (current or former) and the presence of chronic kidney disease were not different in the groups. HOMA-IR correlated significantly with several baseline variables, including BMI (r=0.45, P<0.0001), high-density lipoprotein (r=–0.32, P<0.0001), triglycerides (r=0.22, P<0.0001), and CRP (r=0.12, P=0.0002). There was no correlation between HOMA-IR and LDL (r=0.03, P=0.05) or total cholesterol (r=0.01, P=NS).


View this table:
[in this window]
[in a new window]

  		Table 2. Age- and Gender-Adjusted Characteristics by HOMA-IR Quartile

Age- and gender-adjusted PAD prevalence estimates increased in a graded fashion in increasing HOMA-IR quartiles: 5.0% (SE, 0.8%) in quartile 1, 5.4% (SE, 0.9%) in quartile 2, 6.1% (SE, 0.7%) in quartile 3, and 7.8% (SE, 1.1%) in quartile 4 (P=0.037, {chi}2 test) (Figure 1). Compared with subjects in the lowest HOMA-IR quartile, subjects in increasing quartiles had a graded increase in odds of PAD: OR=1.24 (95% CI, 0.8 to 2.0) for quartile 2, OR=1.53 (95% CI, 0.96 to 2.4) for quartile 3, and OR=1.88 (95% CI, 1.2 to 3.0) for quartile 4 (P for trend=0.009) (Table 3, unadjusted).


Figure 1189966
View larger version (10K):
[in this window]
[in a new window]

  		Figure 1. Age- and gender-standardized PAD prevalence (%) in increasing HOMA-IR quartiles (Q). There is a graded increase in PAD prevalence in increasing HOMA-IR quartiles (P=0.037 by {chi}2 test).


View this table:
[in this window]
[in a new window]

  		Table 3. Multivariable Logistic Regression Analysis of the Association of HOMA-IR and PAD

In a multivariable model adjusting for age, gender, and race/ethnicity (Table 3, model 1), HOMA-IR remained associated with PAD with increasing odds of PAD across HOMA-IR quartiles: OR=1.19 (95% CI, 0.8 to 1.9) for quartile 2, OR=1.4 (95% CI, 0.9 to 2.3) for quartile 3, and OR=1.83 (95% CI, 1.2 to 2.9) for quartile 4 compared with subjects in HOMA-IR quartile 1 (P for trend=0.015). In further analyses also adjusting for traditional atherosclerotic risk factors (hypertension, hyperlipidemia, and smoking) and BMI (Table 3, model 2), the linear association between HOMA-IR quartiles and PAD persisted (P for trend=0.039), and quartile 4 had a >2-fold-increased odds of PAD (OR, 2.07; 95% CI, 1.1 to 3.9) compared with quartile 1. Finally, the magnitude and direction of the association between HOMA-IR and PAD persisted after additional adjustment for nontraditional factors related to PAD, including chronic kidney disease and CRP (P for trend=0.047), and subjects in quartile 4 had an OR of 2.06 (95% CI, 1.1 to 4.0) compared with those in quartile 1 (Table 3, model 3). Additional adjustment for diabetes resulted in a marginal attenuation of the association of insulin resistance with PAD (P for trend=0.058), although subjects in the highest HOMA-IR quartile continued to have an {approx}2-fold increase in the odds of PAD (OR, 1.96; 95% CI, 1.03 to 3.8). After adjustment for hemoglobin A1c as a measure of recent glycemic control instead of diabetes, the relationship remained statistically significant (P for trend=0.047) (Table 3).

These findings were unchanged when HOMA-IR was used as a continuous variable (after log transformation to improve normality). Using a multivariable model accounting for age, gender, race/ethnicity, hypertension, hyperlipidemia, smoking, BMI, chronic kidney disease, and CRP, we found that a 1-unit increase in log-HOMA conferred a 33% increased odds of PAD (OR, 1.33; 95% CI, 1.03 to 1.70; P=0.029). This relationship persisted even after additional adjustment for diabetes (OR, 1.30; 95% CI, 1.0 to 1.67; P=0.047) or hemoglobin A1c (OR, 1.36; 95% CI, 1.02 to 1.8; P=0.036).

Given the recognized relationship between insulin resistance and diabetes, a well-established risk factor for PAD, we repeated our analyses excluding subjects with diabetes to evaluate the association of HOMA-IR with PAD independently of the effect of diabetes. We excluded all subjects with diabetes (n=485, including those with self-report of diabetes, those taking insulin or oral agents, and subjects with a fasting blood glucose level >126 mg/dL or nonfasting level >200 mg/dL), leaving 2757 subjects remaining for analysis. In this nondiabetic sample population, there remained a graded increase in PAD prevalence across increasing HOMA-IR quartiles, with prevalence estimates of 3.8% (SE, 0.69%), 4.7% (SE, 0.94%), 5.7% (SE, 0.79%), and 6.1% (SE, 1.38%) across the 4 quartiles, respectively (P=0.24, {chi}2 text). In univariate logistic regression analysis, a 1-quartile increase in HOMA-IR was associated with an 18% increased odds of PAD (OR, 1.18; 95% CI, 0.98 to 1.42). Additionally, compared with subjects in the lowest HOMA-IR quartile (in an unadjusted model), subjects in increasing quartiles maintained a graded increase in odds of PAD: OR=1.24 (95% CI, 0.8 to 1.97) for quartile 2, OR=1.52 (95% CI, 0.92 to 2.5) for quartile 3, and OR=1.62 (95% CI, 0.9 to 2.90) for quartile 4. As expected, exclusion of nearly 500 individuals from our sample population attenuated the associations between HOMA-IR and PAD; nonetheless, a graded increase in PAD prevalence and graded increases in the odds of PAD by increasing HOMA-IR quartiles were still observed.

Association of CRP and PAD
To evaluate the relationship between CRP and PAD, CRP was first categorized as low (<1 mg/L), intermediate (1 to 3 mg/L), or high (>3 mg/L) according to published American Heart Association/Centers for Disease Control guidelines.35 There was a significant graded increase in PAD prevalence according to CRP category, with prevalence rates of 3.3% (SE, 0.7%), 5.5% (SE, 0.8%), and 6.8% (SE, 0.8%) for CRP levels of <1, 1 to 3, and >3 mg/L, respectively (P=0.003, {chi}2 test). Compared with subjects with a low CRP (<1 mg/L), subjects with a high CRP (>3 mg/L) had a significantly increased odds of PAD with an OR of 2.2 (95% CI, 1.3 to 3.6; P=0.003). Adjusting for age, gender, race/ethnicity, hypertension, hyperlipidemia, smoking status, and chronic kidney disease, we found a significant association between CRP and PAD (OR, 1.02; 95% CI, 1.0 to 1.03; P=0.014 for a 1-mg/L change).

Influence of Insulin Resistance on the Association of CRP and PAD
Given previous conflicting data suggesting that the association of inflammation with atherosclerosis may be altered in states of insulin resistance,25,26 we examined whether the association of CRP with PAD is modified by the presence of insulin resistance. We analyzed the association of CRP with PAD in analyses stratified by median HOMA-IR level (1.86). Among subjects without insulin resistance, there was a graded increase in PAD prevalence among increasing CRP categories, with prevalence estimates of 2.2% (SE, 1.0%), 4.4% (SE, 0.9%), and 6.7% (SE, 1.1%) for CRP levels of <1, 1 to 3, and >3 mg/L, respectively (P=0.007, {chi}2 test) (Figure 2). Expressed as an OR, CRP >3 mg/L significantly increased the likelihood of PAD compared with a CRP <1 mg/L (OR, 3.2; 95% CI, 1.2 to 8.4; P=0.02) in subjects without insulin resistance. However, the association was markedly blunted in subjects with insulin resistance. Subjects with insulin resistance but low CRP (<1 mg/L) had a notably higher prevalence of PAD compared with subjects with low CRP without insulin resistance (5.5% [SE, 0.8%] versus 2.2% [SE, 1.0%]; P=0.019). In the insulin-resistant group, PAD prevalence rates increased slightly but not significantly, from 5.5% (SE, 0.8%) to 6.5% (SE, 1.1%) and 6.9% (SE, 1.0%) in increasing CRP categories (P=0.56, {chi}2 test) (Figure 2). CRP was no longer significantly associated with PAD in subjects with insulin resistance (OR, 1.3; 95% CI, 0.8 to 2.1; P=0.31). We further confirmed that the association of CRP and PAD was significantly different in insulin-sensitive and insulin-resistant subjects (P for interaction term=0.08).


Figure 2189966
View larger version (17K):
[in this window]
[in a new window]

  		Figure 2. Unadjusted PAD prevalence (%) in increasing CRP categories (<1, 1 to 3, and >3 mg/L) in groups stratified by the absence or presence of insulin resistance (defined as having a HOMA-IR below or above the median value of 1.86, respectively). In the absence of insulin resistance, there is a robust relationship between increasing CRP category and prevalence of PAD, with a PAD prevalence of 2.2%, 4.4%, and 6.7% in increasing CRP categories (P=0.007). However, in the presence of insulin resistance, the relationship between CRP and PAD is significantly blunted, with PAD prevalence rates of 5.5%, 6.5%, and 6.9% (P=0.56). Probability values are generated by the {chi}2 test.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowConclusions
 down arrowReferences
 
We examined the interrelationships between inflammation, insulin resistance, and PAD in this nationally representative sample population and found that insulin resistance, indicated by HOMA-IR, is strongly associated with PAD and that the presence of insulin resistance attenuates the association between CRP and PAD. Furthermore, this is the first study to illustrate the association of PAD and a direct measure of insulin resistance, HOMA-IR, a simple method that uses plasma insulin and glucose in a single fasting blood sample. HOMA-IR has previously been reported only in relation to cardiovascular6–8 and cerebrovascular disease.15–18 Indeed, we found a roughly 25% increased odds of PAD for each 1-quartile increase in HOMA-IR, a finding that remained consistent despite adjustment for typical atherosclerotic risk factors, factors related to insulin resistance (ie, BMI), and glycemic control (hemoglobin A1c). In addition, although the trend across quartiles was marginally no longer statistically significant after adjustment for diabetes, the point estimates were essentially unchanged, and subjects in the highest HOMA-IR quartile continued to have a nearly 2-fold increased odds of PAD. Using HOMA-IR as a continuous variable, we found a strong relationship between PAD and insulin resistance that persisted even after additional adjustment for diabetes or hemoglobin A1c. These data suggest that insulin resistance may have an association with PAD along the entire spectrum of insulin resistance and distinct from the impact of diabetes. Even after the exclusion of subjects with diabetes, there were graded increases in PAD prevalence with increasing HOMA-IR quartiles, although the associations between HOMA-IR and PAD were no longer statistically significant. Our data support prior observations that PAD is associated with the metabolic syndrome11,12,36 and glucose intolerance,13 both surrogate markers of insulin resistance.

In contrast to the limited data on the association of insulin resistance and PAD, the link between inflammation and PAD has been well established. Our demonstration of a strong association between CRP and PAD is consistent with prior epidemiological data and prospective studies linking inflammation with atherosclerosis in the coronary and peripheral arterial beds.1–3,19–23,37 However, much of the information on inflammation and atherosclerosis has been generated in healthy individuals. Less clear is whether this relationship persists in individuals with established cardiovascular risk factors such as diabetes. Sakkinen et al26 studied the relationship between CRP and myocardial infarction over a 20-year period, and although they found a positive relationship between CRP and myocardial infarction in the overall population, the association was abolished in individuals with diabetes. The same group also showed no significant relationship between CRP and stroke among patients with diabetes or hypertension.25 Prospective data from the Strong Heart Study in an American Indian population found no predictive value of CRP for incident cardiovascular events in diabetic individuals.38 In contrast, the Women’s Health Study2 found that CRP added prognostic information regarding cardiovascular events even in subjects with the metabolic syndrome, and a study by Schulze et al27 found a strong relationship between CRP and cardiovascular events among men with diabetes. However, none of these studies focused specifically on PAD, and none directly examined the role of insulin resistance.

Given the conflicting data on the relationship of CRP and vascular disease among subjects with diabetes and metabolic syndrome, we explored the possibility that insulin resistance in particular might influence the relationship between CRP and PAD. Indeed, our analysis found a strong association between CRP and PAD among individuals who were insulin sensitive. However, this association was no longer evident in subjects with insulin resistance.

The attenuation of the relationship between CRP and PAD in the presence of insulin resistance may be explained in part by the close interrelationship of inflammation and insulin resistance in vascular disease.28–30,39 Extensive experimental data demonstrate that inflammation leads to impaired insulin metabolic signaling, resulting in insulin resistance.39 Insulin resistance may in turn exacerbate inflammation via increased cytokine and adipochemokine expression (including tumor necrosis factor alpha-{alpha}, interleukin-6, leptin, monocyte chemoattractant protein-1, plasminogen activator inhibitor-1, and others), elevation of free fatty acid levels, and impaired endothelial nitric oxide synthase activity.39,40 The reciprocal interaction of inflammation and insulin resistance creates a cycle of further increasing cardiovascular risk.

These findings also support the notion that atherogenesis results from the complex interplay of multiple atherosclerotic risk factors, each of variable influence in different vascular beds. In individuals with few risk factors, inflammation may have a relatively large contribution to the development of atherosclerosis. In contrast, in the presence of a potent cardiovascular risk factor, insulin resistance, the relative contribution of inflammation to the pathogenesis of atherosclerosis may be diminished. In our study, subjects with insulin resistance but without inflammation (CRP <1 mg/L) already had a high prevalence of PAD (5.5%) compared with those who were insulin sensitive and without inflammation (2.2%). Among insulin-resistant subjects, the presence of inflammation then resulted in only a marginal increase in PAD prevalence (to 6.9% in the highest CRP category) that was not statistically significant. Whether these data imply that insulin resistance reduces the association of inflammation and PAD by a distinct effect on vascular function or simply by increasing inflammation, they highlight the complexity of the interaction of these risk factors in PAD and suggest that the role of inflammation in PAD may be modified in individuals with insulin resistance.

Additionally, although there are common risk factors for the development of vascular disease, the impact of specific risk factors on the development of disease is not the same in the peripheral vascular bed as in the coronary or cerebrovascular circulations.41 Indeed, cigarette smoking, one of the strongest risk factors for the development of PAD, was shown in the Edinburgh Artery Study42 to have a greater impact on PAD (OR, 1.8 to 5.6 for the risk of PAD in smokers versus nonsmokers) than on coronary artery disease (OR, 1.1 to 1.6). In contrast, hypertension and hyperlipidemia, potent risk factors for coronary atherosclerosis, appear to have less impact on the development of PAD, with a 10-mg/dL increase in total cholesterol conferring only a 10% increased risk of PAD.41 These findings suggest that individual risk factors may have variable impact on different vascular beds, and as such, a focused analysis of the impact of insulin resistance on PAD is warranted and may shed light on the differential pathophysiology of PAD compared with CAD and cerebrovascular disease.

These pathophysiological differences may explain in part the differences observed between our results and the findings of the Women’s Health Study2 and a study by Schulze et al,27 which suggest that CRP adds prognostic information regarding incident cardiovascular disease in subjects with the metabolic syndrome2 or diabetes27 at baseline. Our results also stand in contrast to a cross-sectional study from Vu et al43 in a smaller NHANES cohort suggesting that CRP remains associated with PAD even in patients with metabolic syndrome or diabetes, although not in those with established cardiovascular disease. The discrepancy is explained in part by differences in statistical methodology (the authors used the group with low CRP and no established disease as the reference population for all comparisons) and use of metabolic syndrome as opposed to a direct measure of insulin resistance.

These data are derived from a nationally representative cohort and therefore are generalizable to the US adult population. The ABI method has been demonstrated to have excellent sensitivity and specificity for the diagnosis of PAD.10 Despite these strengths, potential limitations of the present study merit consideration. In NHANES, the ABI was calculated from the blood pressure in only 1 arm, raising the potential for misclassification by not excluding the possibility of subclavian stenosis. Additionally, our analysis was limited to the subset of participants with ABI measurements who had a fasting blood sample drawn, reducing our sample size and potentially limiting power. However, our final sample population was nonetheless substantial, consisting of >3200 individuals in whom there were 256 cases of PAD. We also are limited by the lack of established threshold values of HOMA-IR for indicating the presence or absence of insulin resistance. Prior studies have used quartiles8 or quintiles,6 and given the lack established guidelines, we elected to use standard median and quartile cut points in our analysis. Additionally, there are notable differences in clinical variables by HOMA-IR quartile; even with multivariable models, there may be confounding that may not be adequately accounted for in our statistical models. Finally, the cross-sectional nature of our study does not allow us to draw conclusions regarding causality, and prospective studies are required to clarify any temporal relationship and to delineate the true causal relationships between inflammation, insulin resistance, and PAD.


*    Conclusions
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *Conclusions
down arrowReferences
 
Insulin resistance is strongly and independently associated with PAD. The presence of insulin resistance attenuates the association of inflammation with PAD. These data establish a role of insulin resistance in PAD and suggest that future studies are warranted to better understand the complex interplay of inflammation and insulin resistance in peripheral arterial disease.


*    Acknowledgments
 
Sources of Funding

Dr Creager is the Simon C. Fireman Scholar in Cardiovascular Medicine. Dr Pande was supported by a Research Career Development Award (K12 HL083786) from the National Heart, Lung, and Blood Institute (NHLBI) and by NHLBI training grant T32 HL07604. Dr Perlstein was supported by an American College of Cardiology Foundation/Merck Research Fellowship Award training grant and by NHLBI training grant T32 HL07604. Dr Beckman was supported by American Diabetes Association career development award 1-06-CD-01. This work also was supported by a grant from the NHLBI (R01 HL075771).

Disclosures

None.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 up arrowConclusions
 *References
 

  1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836–843.[Abstract/Free Full Text]
  2. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107: 391–397.[Abstract/Free Full Text]
  3. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997; 17: 1121–1127.[Abstract/Free Full Text]
  4. Howard G, O’Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis: the Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation. 1996; 93: 1809–1817.[Abstract/Free Full Text]
  5. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med. 2002; 19: 470–475.[CrossRef][Medline] [Order article via Infotrieve]
  6. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002; 25: 1177–1184.[Abstract/Free Full Text]
  7. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggeo M. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002; 25: 1135–1141.[Abstract/Free Full Text]
  8. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care. 2007; 30: 318–324.[Abstract/Free Full Text]
  9. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45: S5–S67.[CrossRef][Medline] [Order article via Infotrieve]
  10. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation. 2006; 113: e463–e654.[Free Full Text]
  11. Brevetti G, Schiano V, Sirico G, Giugliano G, Laurenzano E, Chiariello M. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg. 2006; 44: 101–107.[CrossRef][Medline] [Order article via Infotrieve]
  12. Rana JS, Jansen AC, Zwinderman AH, Nieuwdorp M, van Aalst-Cohen ES, Jukema JW, Trip MD, Kastelein JJ. Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia. Diabetes Care. 2006; 29: 1125–1127.[Free Full Text]
  13. Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E. Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: the DESIR study. Atherosclerosis. 2007; 190: 84–89.[CrossRef][Medline] [Order article via Infotrieve]
  14. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23: 57–63.[Abstract]
  15. Ahmad J, Ahmed F, Siddiqui MA, Hameed B, Ahmad I. Inflammation, insulin resistance and carotid IMT in first degree relatives of north Indian type 2 diabetic subjects. Diabetes Res Clin Pract. 2006; 73: 205–210.[CrossRef][Medline] [Order article via Infotrieve]
  16. Atabek ME, Pirgon O, Kivrak AS. Evidence for association between insulin resistance and premature carotid atherosclerosis in childhood obesity. Pediatr Res. 2007; 61: 345–349.[CrossRef][Medline] [Order article via Infotrieve]
  17. Hidvegi T, Szatmari F, Hetyesi K, Biro L, Jermendy G. Intima-media thickness of the carotid arteries in subjects with hyperinsulinaemia (insulin resistance). Diabetes Nutr Metab. 2003; 16: 139–144.[Medline] [Order article via Infotrieve]
  18. Yang B, Li TD, Wang JS, Zhi G, Jin WS, Xu Y. Insulin resistance and carotid atherosclerosis in 221 patients with potential hyperglycemia. Chin Med Sci J. 2005; 20: 108–111.[Medline] [Order article via Infotrieve]
  19. Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999–2002. Am J Cardiol. 2005; 96: 1579–1583.[CrossRef][Medline] [Order article via Infotrieve]
  20. McDermott MM, Guralnik JM, Corsi A, Albay M, Macchi C, Bandinelli S, Ferrucci L. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J. 2005; 150: 276–281.[CrossRef][Medline] [Order article via Infotrieve]
  21. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998; 97: 425–428.[Abstract/Free Full Text]
  22. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 2002; 106: 820–825.[Abstract/Free Full Text]
  23. Owens CD, Ridker PM, Belkin M, Hamdan AD, Pomposelli F, Logerfo F, Creager MA, Conte MS. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg. 2007; 45: 2–9.[CrossRef][Medline] [Order article via Infotrieve]
  24. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol. 2005; 96: 1374–1378.[CrossRef][Medline] [Order article via Infotrieve]
  25. Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, Tracy RP. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003; 107: 2016–2020.[Abstract/Free Full Text]
  26. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002; 55: 445–451.[CrossRef][Medline] [Order article via Infotrieve]
  27. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004; 27: 889–894.[Abstract/Free Full Text]
  28. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102: 42–47.[Abstract/Free Full Text]
  29. Chen J, Wildman RP, Hamm LL, Muntner P, Reynolds K, Whelton PK, He J. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004; 27: 2960–2965.[Abstract/Free Full Text]
  30. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860–867.[CrossRef][Medline] [Order article via Infotrieve]
  31. National Health and Nutrition Examination Survey 2003–2004. Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l10am_c.pdf. Accessed December 26, 2007.
  32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412–419.[CrossRef][Medline] [Order article via Infotrieve]
  33. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145: 247–254.[Abstract/Free Full Text]
  34. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27: 1487–1495.[Abstract/Free Full Text]
  35. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499–511.[Free Full Text]
  36. Lahoz C, Vicente I, Laguna F, Garcia-Iglesias MF, Taboada M, Mostaza JM. Metabolic syndrome and asymptomatic peripheral artery disease in subjects over 60 years of age. Diabetes Care. 2006; 29: 148–150.[Free Full Text]
  37. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999; 99: 237–242.[Abstract/Free Full Text]
  38. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, Roman M, Devereux RB, Fabsitz RR, Tracy RP, Robbins D, Davidson M, Ahmed A, Howard BV. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005; 112: 1289–1295.[Abstract/Free Full Text]
  39. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793–1801.[CrossRef][Medline] [Order article via Infotrieve]
  40. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep. 2003; 3: 279–288.[Medline] [Order article via Infotrieve]
  41. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation. 2004; 109: 2617–2625.[Free Full Text]
  42. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, Ruckley CV. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992; 135: 331–340.[Abstract/Free Full Text]
  43. Vu JD, Vu JB, Pio JR, Malik S, Franklin SS, Chen RS, Wong ND. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005; 96: 655–658.[CrossRef][Medline] [Order article via Infotrieve]
 

CLINICAL PERSPECTIVE

Peripheral arterial disease (PAD) is an important manifestation of systemic atherosclerosis. Systemic inflammation and insulin resistance are closely linked pathological states, and each contributes to the development of atherosclerosis. However, the specific association of insulin resistance with PAD and the influence of insulin resistance on the relationship between inflammation and PAD have not been established. Using data from the National Health and Nutrition Examination Survey 1999 to 2004, we found that insulin resistance, as measured by the homeostasis model of insulin resistance, is strongly associated with PAD independently of known cardiovascular risk factors. Furthermore, we found that the presence of insulin resistance blunts the association between inflammation, as measured by C-reactive protein, and PAD. These findings suggest a direct link between PAD and insulin resistance along its entire spectrum and highlight the complex interplay of insulin resistance and inflammation in atherosclerosis.


*    Footnotes
 
Guest Editor for this article is William Hiatt, MD.


Related Article:

Clinical Summaries
Circulation 2008 118: 1-2. [Extract] [Full Text]




This Article
Free upon publication Free Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
118/1/33    most recent
CIRCULATIONAHA.107.721878v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pande, R. L.
Right arrow Articles by Creager, M. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pande, R. L.
Right arrow Articles by Creager, M. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Peripheral Arterial Disease
Related Collections
Right arrow Risk Factors
Right arrow Peripheral vascular disease
Right arrow Epidemiology
Right arrowRelated Article

Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.